Learn More
BACKGROUND There have been no clinical trials in resource-rich regions that have addressed the question of which highly active antiretroviral therapy (HAART) regimens are more effective for optimal viral response in antiretroviral-naive, human immunodeficiency virus (HIV)-infected pregnant women. METHODS Data on 240 HIV-1-infected women starting HAART(More)
Highly active antiretroviral therapy (HAART) may be associated with adverse pregnancy outcomes. Among 4372 live births in the European Collaborative Study, the prematurity rate increased to 24.9% in 2000-2004. Antenatal HAART use initiated pre-pregnancy was strongly associated with prematurity (AOR 2.05, 95% CI 1.43, 2.95), particularly severe prematurity.(More)
OBJECTIVE To describe pregnancy outcomes among clade C HIV-infected and uninfected women in South Africa. DESIGN A longitudinal cohort study. METHODS Pregnant women attending 9 rural/urban antenatal clinics were prospectively recruited and followed up. Women were seen at the clinic or at home after delivery on 4 occasions after enrollment: 2 times(More)
BACKGROUND Rapid testing of pregnant women aims to increase uptake of HIV testing and results and thus optimize care. We report on the acceptability of HIV counselling and testing, and uptake of results, before and after the introduction of rapid testing in this area. METHODS AND PRINCIPAL FINDINGS HIV counsellors offered counselling and testing to women(More)
BACKGROUND Considerable uncertainty remains as to whether early initiation of antiretroviral therapy (ART) in children with vertically acquired human immunodeficiency virus (HIV) infection increases the benefit in terms of immunological response. METHODS The association between immunological outcome and early initiation of and/or more-potent ART was(More)
OBJECTIVES To examine growth of children by maternal and infant HIV status allowing for infant feeding mode. DESIGN Women enrolled into a nonrandomized intervention cohort. METHODS Children of HIV-infected and uninfected women weighed and assessed for HIV status, monthly: from birth to 9 months; quarterly: 10-24 months. Daily infant feeding practices(More)
OBJECTIVE To assess pregnancy levels and patterns of HIV RNA in the absence of antiretroviral therapy, while appropriately adjusting for potential confounders, including maternal immune status and race. METHODS Data on > or = 1 antenatal HIV RNA measurements were available for 333 untreated HIV-infected pregnant women enrolled in the European(More)
  • 1